Loading people...
Dirk Reyn is the Managing Partner and Co-Founder at Bioqube Ventures, based in the Antwerp Metropolitan Area, Belgium. Before transitioning to venture capital, he spent over two decades in executive roles at major pharmaceutical firms, including serving as Vice President of New Business Development in Europe for Johnson & Johnson's Janssen Pharmaceutica and holding management positions at Eli Lilly. In 2006, he co-founded and served as Chief Executive Officer of Movetis NV, leading the company through a 2009 initial public offering on Euronext Brussels and its subsequent €428 million acquisition by Shire in 2010. At Bioqube Ventures, he co-manages the €110 million Bioqube Factory Fund I, which recently participated in a €40 million Series A funding round for Dualyx. Reyn leverages his background in commercial operations to focus on transitioning early-stage scientific discoveries into viable therapeutic businesses.
Dirk Reyn stands as a pivotal figure in the European life sciences venture capital landscape, serving as a Managing Partner and co-founder of Bioqube Ventures. His leadership at Bioqube Ventures is instrumental in shaping the firm's strategy to identify, fund, and build transformative early-stage biotechnology and pharmaceutical companies. Bioqube Ventures is renowned for its hands-on approach, often incubating ventures from inception within its unique ecosystem, the Bioqube Factory, which fosters scientific breakthroughs into viable commercial entities.
Reyn's investment philosophy is deeply rooted in his extensive operational experience within the biopharmaceutical industry. Bioqube Ventures primarily targets early-stage opportunities, focusing on novel therapeutic platforms, drug discovery, and innovative healthcare solutions. The firm seeks to back companies that are poised to address significant unmet medical needs, leveraging cutting-edge science and technology. Under Reyn's guidance, Bioqube Ventures actively supports its portfolio companies through strategic guidance, operational expertise, and access to a vast network of industry professionals.
Before co-founding Bioqube Ventures, Dirk Reyn built an impressive career marked by significant leadership roles at global biopharmaceutical companies. Most notably, he served as the Chief Executive Officer of UCB, a multinational biopharmaceutical company, where he played a crucial role in its strategic direction and growth. Prior to UCB, Reyn also held the CEO position at Innogenetics, a diagnostics and therapeutics company, further solidifying his expertise across various facets of the life sciences sector. His tenure in these leadership roles provided him with invaluable insights into drug development, market access, and global commercialization strategies, knowledge he now applies to mentor and guide the next generation of biotech entrepreneurs.
Dirk Reyn's career background is characterized by a blend of scientific acumen and business leadership. He has also contributed to the broader life sciences ecosystem through various board memberships, including positions at Galapagos, VIB (Flanders Institute for Biotechnology), and FlandersBio. These roles underscore his commitment to fostering innovation and growth within the European biotech community.
While Bioqube Ventures has a diverse portfolio, some notable investments under its umbrella, reflecting Reyn's strategic vision, include companies like Azafaros, focused on rare metabolic disorders; Confo Therapeutics, developing novel GPCR modulators; and miDiagnostics, pioneering disruptive diagnostic solutions. These investments exemplify Bioqube Ventures' commitment to backing companies with strong scientific foundations and the potential for significant patient impact. Through his work at Bioqube Ventures, Dirk Reyn continues to be a driving force in translating scientific discovery into tangible healthcare solutions, making a lasting impact on the global life sciences industry.
Dirk Reyn is a Managing Partner and co-founder of Bioqube Ventures, a leading European venture capital firm focused on early-stage life sciences investments. He has a distinguished background as a CEO of major biopharmaceutical companies like UCB and Innogenetics.
Dirk Reyn, through Bioqube Ventures, primarily invests in early-stage life sciences companies, focusing on novel therapeutic platforms, drug discovery, and innovative biotech solutions with significant medical potential.
Dirk Reyn works as a Managing Partner at Bioqube Ventures, a prominent European venture capital firm specializing in the life sciences sector.
